jkool said:Yes that may be problem for someone cashed up to their eyeballsBut seriously around 10k-20k shouldnt be difficult to obtain/discard on daily basis however if you wanna trade it in/out very frequently than yes you better look elsewhere.
Stock for me its a buy and hold for a long term gain.
Date: 12/4/2007
Author: Margie Sheedy
Source: The Sydney Morning Herald --- Page: 27
There is often a lot of staff churn in the healthcare sector in Australia. This is not the case at Blackmores, which sells vitamins and health supplements. This company actively helps staff further their careers, nurtures them, gives them time to train for different roles and gives them family leave. Blackmores believes in nurturing the health and well-being of staff, who becoming living examples of the company's approach to health. Recruiters believe that companies have to actively work to keep staff. They cannot just give money, because many staff members want career development and flexible working routines. Blackmores is an ideal employer and others will have to copy it in order to keep the best staff.
Blackmore's has always been a strange share. It still has a great growth rate of about 10%. It's balance sheet is in great condition and cash flow is strong.
The company is undervalued a little and properly should be trading at around $24 again. There is no reason why it shouldn't be trading at around that price as their market is never really going to suffer as people need health care products no matter what economy we are in.
I would say it is a long term hold - but then again I don't have any of Blackmore's shares.
Business Description
Blackmores (BKL) is focused on vitamin and mineral supplements and natural skin and hair treatment products throughout Australasia. The company also provides information services and carries out research and development into natural preventative health care.
Company Strategy
Organic growth is driven by high levels of research and development focusing on areas where health awareness is high such as obesity, cardiovascular and joint problems. Offshore diversification is ongoing, particularly across Asia where the regulatory burden is lower. As production capacity at the new Sydney facility increases BKL will target additional regional Asian markets with similar demographics. BKL reported underlying FY07 NPAT up 15.4% to $16.7m compared to our $17.6m forecast. Sales revenue grew 16% to $171.7m driven by new product launches and strength across all business units. Gross profit margins firmed 77 bpts to 58.2% mainly due to improved sourcing and scale benefits in the production process. EBIT grew 21.2% to $24.2m with EBIT margin up 60 bpts to 14.1%. A final dividend of 46 cps is payable September 24, bringing the fully franked full year dividend to 81 cps.
BKL is certainly one of my favorites. Comments like it is too pricey don't surprise me as it trades on a high multiple but at what point does too pricey become a bargain. Do you wait hoping for an Sp correction, which in the case of BKL will be very minimal due to growth and low liquidity, or do you buy hoping that earnings continue to grow. The answer is that you need to look at what your own required rate of return is and then you can determine whether BKL is an opportunity. Companies of quality very rarely present great buying opportunities unless they befall bad times.
I'm sure it's a great company if Roger likes it.
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?